Indicators of hemostasis and fibrinolysis systems and systemic inflammatory response in patients with newly diagnosed sarcoidosis after COVID-19
- Authors: Abdullaev R.Y.1, Shorokhova V.A.1, Makaryants N.N.1, Komissarova O.G.1,2
-
Affiliations:
- Central Research Institute of Tuberculosis
- N.I. Pirogov National Research Medical University, Ministry of Health of Russia
- Issue: Vol 34, No 12 (2023)
- Pages: 40-45
- Section: From Practice
- URL: https://journals.eco-vector.com/0236-3054/article/view/625579
- DOI: https://doi.org/10.29296/25877305-2023-12-08
- ID: 625579
Cite item
Open Access
Access granted
Abstract
Objective. To study the indicators of hemostasis and fibrinolysis systems, as well as the systemic inflammatory response in patients with newly diagnosed sarcoidosis after infection caused by SARS-CoV-2.
Material and methods. A prospective analysis of the indicators of hemostasis and fibrinolysis systems, as well as the systemic inflammatory response of 20 patients with sarcoidosis, after COVID-19, who were on inpatient treatment in Central TB Research Institute. The patients were divided into 2 groups. The first group included 10 patients with sarcoidosis, who had suffered COVID-19 (the main group). The comparison group consisted of 10 patients with sarcoidosis without a history of COVID-19.
Results. It was found, that in patients with newly diagnosed sarcoidosis, who underwent COVID-19, there is a hypercoagulation shift in the hemostasis and fibrinolysis system. This was evidenced by a significant shortening of the indicators of APTT, PT and an increase in the level of D-dimer compared to both healthy and patients, who had not undergone COVID-19. In addition, laboratory manifestations of systemic inflammation were most pronounced in patients with sarcoidosis who underwent COVID-19. Probably, changes in the hemostasis and fibrinolysis system occurred within the framework of a systemic inflammatory response.
Full Text
About the authors
R. Yu. Abdullaev
Central Research Institute of Tuberculosis
Author for correspondence.
Email: rizvan0403@yandex.ru
ORCID iD: 0000-0002-9105-9264
MD, Professor
Russian Federation, MoscowV. A. Shorokhova
Central Research Institute of Tuberculosis
Email: rizvan0403@yandex.ru
ORCID iD: 0000-0002-7143-3204
Candidate of Medical Sciences
Russian Federation, MoscowN. N. Makaryants
Central Research Institute of Tuberculosis
Email: rizvan0403@yandex.ru
ORCID iD: 0000-0002-6390-8759
MD
Russian Federation, MoscowO. G. Komissarova
Central Research Institute of Tuberculosis; N.I. Pirogov National Research Medical University, Ministry of Health of Russia
Email: rizvan0403@yandex.ru
ORCID iD: 0000-0003-4427-3804
MD
Russian Federation, Moscow; MoscowReferences
- Абдуллаев Р.Ю., Комиссарова О.Г. Лабораторные проявления короновирусной инфекции COVID-19. Врач. 2020; 31 (5): 3–6 [Abdullaev R., Komissarova O. Laboratory indicators of coronаvirus infection COVID-19. Vrach. 2020; 31 (5): 3–6. (in Russ.)]. doi: 10.29296/25877305-2020-05-01
- Бородулина Е.А., Широбоков Я.Е., Гладунова Е.П. и др. Диагностика и фармакотерапия вирус-ассоциированных поражений легких. Клиническая фармакология и терапия. 2020; 29 (3): 61–6 [Borodulina E.A., Shirobokov Y.E., Gladunova E.P. et al. Virus-associated lung disease. Clin Pharmacol Ther. 2020; 29 (3): 61–6 (in Russ.)]. doi: 10.32756/0869-5490-2020-3-61-66
- Визель А.А., Визель И.Ю., Амиров Н.Б. Эпидемиология саркоидоза в Российской Федерации. Вестник современной клинической медицины. 2017; 10 (5): 66–73 [Vizel А.А., Vizel I.Yu., Amirov N.B. Epidemiology of sarcoidosis in the Russian Federation. The Bulletin of Contemporary Clinical Medicine. 2017; 10 (5): 66–73 (in Russ.)]. doi: 10.20969/VSKM.2017.10(5).66-73
- Старшинова А.А., Малкова А.М., Зинченко Ю.С. и др. Аутоиммунная составляющая в этиологии саркоидоза. Туберкулез и болезни легких. 2020; 98(5): 54–62 [Starshinova A.A., Malkova A.M., Zinchenko Yu.S., et al. Autoimmune component in the etiology of sarcoidosis. Tuberculosis and Lung Diseases. 2020; 98 (5): 54–62 (in Russ.)]. doi: 10.21292/2075-1230-2020-98-5-54-62
- Brito-Zerón P., Gracia-Tello B., Robles A. et al. Characterization and Outcomes of SARS-CoV-2 Infection in Patients with Sarcoidosis. Viruses. 2021; 13 (6): 1000. doi: 10.3390/v13061000
- Brito-Zerón P., Pérez-Álvarez R., Ramos-Casals M. Sarcoidosis. Med Clin (Barc). 2022; 159 (4):195–204. doi: 10.1016/j.medcli.2022.03.009
- Capaccione K.M., McGroder C., Garcia C. K. et al. COVID-19-induced pulmonary sarcoid: A case report and review of the literature. Clin Imaging. 2022; 83: 152–8. doi: 10.1016/j.clinimag.2021.12.021
- Hadi Y.B., Lakhani D.A., Naqvi S.F.Z. et al. Outcomes of SARS-CoV-2 infection in patients with pulmonary sarcoidosis: A multicenter retrospective research network study. Respir Med. 2021; 187: 106538. doi: 10.1016/j.rmed.2021.106538
- Kahlmann V., Manansala M., Moor C.C. et al. COVID-19 infection in patients with sarcoidosis: susceptibility and clinical outcomes. Curr Opin Pulm Med. 2021; 27 (5): 463–71. doi: 10.1097/MCP.0000000000000812
- Palones E., Pajares V., Lopez L. et al. Sarcoidosis following SARS-CoV-2 infection: Cause or consequence. Respirol Case Rep. 2022; 10 (6): e0955. doi: 10.1002/rcr2.955
- Rabufetti A., Borradori L., Heidemeyer K. et al. New onset of sarcoidosis after COVID-19 infection. J Eur Acad Dermatol Venereol. 2022; 36 (10): e756-e759. doi: 10.1111/jdv.18313
- Rossides M., Darlington P., Kullberg S. et al. Sarcoidosis: Epidemiology and clinical insights. J Intern Med. 2023; 293 (6): 668–80. doi: 10.1111/joim.13629
- Starshinova A., Zinchenko Y., Malkova A. et al. Sarcoidosis and Autoimmune Inflammatory Syndrome Induced by Adjuvants. Life (Basel). 2023; 13 (4): 1047. doi: 10.3390/life13041047
- Strangfeld A., Schafer M., Gianfrancesco M.A. et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021; 80 (7): 930–42. doi: 10.1136/annrheumdis-2020-219498
- Tang N., Li D., Wang X., et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18 (4): 844–7. doi: 10.1111/jth.14768
Supplementary files
